208110-81-0Relevant articles and documents
Separation of geometric isomers of a dicopper complex by using a 19F-labeled ligand: Dynamics, structures, and DFT calculations
Durot, Stephanie,Hossain, Laila H.,Hamman, Sylvain,Jamet, Helene,Orio, Maylis,Gautier-Luneau, Isabelle,Luneau, Dominique,Philouze, Christian,Pierre, Jean-Louis,Belle, Catherine
, p. 7832 - 7840 (2010)
Introducing a fluorine group on two pyridines of the HLCH3 ligand (2,6-bis[(bis(2-pyridylmethyl)amino)methyl]-4-methylphenol) allows the separation of two geometric isomers after complexation by two copper(II) ions. Methods for isolating the is
Fluoro-imidazopyridinylidene Ruthenium Catalysts for Cross Metathesis with Ethylene
Byun, Seunghwan,Seo, Huiyeong,Choi, Jun-Ho,Ryu, Ji Yeon,Lee, Junseong,Chung, Won-Jin,Hong, Sukwon
supporting information, p. 4121 - 4132 (2019/10/16)
A series of ruthenium metathesis catalysts bearing fluorinated imidazo[1,5-a]pyridin-3-ylidene carbenes (F-ImPy) were developed for ethenolysis (cross metathesis with ethylene) of methyl oleate. X-ray crystal structure analysis shows Ru-F interaction, and this fluorine substitution appears to be pivotal to have stable ImPy-Ru precatalysts. Ligand structure was varied for high catalyst activity and cross metathesis selectivity in ethenolysis reaction. F-ImPy-Ru catalysts showed high selectivity in ethenolysis of methyl oleate and thermal robustness under an ethylene atmosphere.
Synthesis of some fluorine-containing pyridinealdoximes of potential use for the treatment of organophosphorus nerve-agent poisoning
Timperley, Christopher M.,Banks, R. Eric,Young, Ian M.,Haszeldine, Robert N.
, p. 541 - 547 (2011/09/15)
Fluoroheterocyclic aldoximes were screened as therapeutic agents for the treatment of anticholinesterase poisoning. 2-Fluoropyridine-3- and -6-aldoxime, and 3-fluoropyridine-2- and -4-aldoxime, were synthesised. Attempts to obtain 3,5,6-trifluoropyridine-2,4-bis(aldoxime) and -2-aldoxime, however, proved unsuccessful. Pentafluorobenzaldoxime was prepared by oximation of pentafluorobenzaldehyde. Acid dissociation constants (pKa) and second-order rate constants (kox-) of the fluorinated pyridinealdoximes towards sarin were measured. 2,3,5,6-Tetrafluoropyridine-4- aldoxime had the best profile: its kox- approached that of the therapeutic oxime P2S (310 vs. 120 l mol-1 min-1), but its higher pKa (9.1 vs. 7.8) fell short of the target figure of 8 required for reactivation of inhibited acetylcholinesterase in vivo. N-alkylation of the fluorinated pyridine-aldoximes may reduce their pK a nearer to 8 and enhance their therapeutic potential. Crown Copyright
SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS
-
Page 37, (2008/06/13)
Compounds of Formula (I) are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8, and Ar in the above Formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).
Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands
-
, (2008/06/13)
Substituted imidazolylmethyl pyridine and pyrazine derivatives that bind to GABAA receptors are provided. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).
Benzimidazole and pyridylimidazole derivatives
-
, (2008/06/13)
This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine
-
, (2008/06/13)
PCT No. PCT/FR97/02097 Sec. 371 Date May 21, 1999 Sec. 102(e) Date May 21, 1999 PCT Filed Nov. 20, 1997 PCT Pub. No. WO98/22459 PCT Pub. Date May 28, 1998The invention concerns novel pyridin-2-yl-methylamine derivatives of formula (I): in which: u represents hydrogen or methyl; v represents hydrogen, chlorine, or methyl; w represents hydrogen, fluorine, or methyl; x represents hydrogen or fluorine; y represents chlorine or methyl; z represents hydrogen, fluorine, chlorine, or methyl; A represents hydrogen, fluorine, chlorine, C1-C5 alkyl, fluoroalkyl, cyclopropyl, a 5-membered aromatic heterocyclic group, alkoxy or alkythio, amino, cyclic amino, or alkoxycarbonyl. These compounds are useful as medicines, in particular as antidepressants or analgesics.
Design and synthesis of a series of 6-substituted-2- pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT(1A) receptors
Vacher, Bernard,Bonnaud, Bernard,Funes, Philippe,Jubault, Nathalie,Koek, Wouter,Assié, Marie-Bernadette,Cosi, Cristina
, p. 5070 - 5083 (2007/10/03)
A search for novel, selective agonists with high intrinsic activity at the 5-HT(1A) subtype of serotonin (5-HT) receptors was undertaken. Mechanistic and thermodynamic considerations led to the design of 6- substituted-2-pyridinylmethylamine as a potential 5-HT(1A) pharmacophore. Various adducts derived from the 6-substituted-2-pyridinylmethylamine moiety were tested for their affinity at 5-HT(1A), α1-adrenergic, and D2- dopaminergic receptors. Compounds with high affinity for 5-HT(1A) receptors (pK(i) ≥ 8) were examined for agonist properties by measuring their ability to inhibit forskolin-stimulated cAMP production in HA7 cells (i.e., HeLa cells permanently transfected with the h5-HT(1A) receptor gene and expressing the h5-HT(1A) receptor protein). Several compounds of the type aryl{4-[(6- substituted-pyridin-2-ylmethylamino)methyl]piperidin-1-yl}methanone had nanomolar affinity for 5-HT(1A) binding sites and were more than 500-fold selective with respect to α1 and D2 sites. Importantly, their 5-HT(1A) agonist properties were demonstrated in HA7 cells where they behaved as potent inhibitors of cAMP accumulation. In particular, (3,4- dichlorophenyl){4-[(6-oxazol-5-ylpyridin-2-ylmethylamino)methyl]piperidin- 1-yl}methanone (70) and (3,4-dichlorophenyl){4-[(6-azetidinopyridin-2- ylmethylamino)methyl]piperidin-1-yl}methanone (36) appeared to be more potent than, and at least as efficacious as, the prototypical 5-HT(1A) agonist (±)-8-OH-DPAT. SAR studies revealed that the pyridine nitrogen atom and the nature and the position of the substituents on the pyridine ring were critically involved in the ability of the compounds to recognize and activate 5-HT(1A) receptors. Structural modifications of the nonpharmacophoric part of the molecule showed, however, that the entire structure was required for affinity at 5-HT(1A) binding sites.
